Global pharmaceutical company, The Medicines Company, announced that the U.S. FDA has approved KENGREAL™ (cangrelor) as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events in patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor (GPI). KENGREAL is a synthetic and reversible small molecule inhibitor of P2Y12, a G protein-coupled receptor and an important regulator in blood clotting that is mainly expressed on the surface of platelets. By inhibition of P2Y12, KENGREAL prevents formation of harmful blood clots in the arteries. PCI, commonly known as coronary angioplasty, is a non-surgical procedure used to open a blocked or narrowed coronary artery. The FDA approval is supported by the CHAMPION PHOENIX study, which demonstrated significant reduction of the rate of periprocedural complications of PCI with cangrelor as compared with clopidogrel. The company expects KENGREAL to be available in the U.S. in July.